UPDATE
: Monday, September 7, 2020
Home
Login
Mobile Version
All
Hospital
Pharma
Bio
Korea‘s Bio Industry
Device/ICT
Policy
People
Life science
Special
Innovation for Survival
Korea’s medical culture series
Korea’s New Candidate Drug Watch List
Special Series in Celebration of KBR's 1st Anniversary
Interview with foreign envoys
Special Series in Celebration of KBR’s 2nd Anniversary
Interview with global pharma
Special Series in Celebration of KBR’s 3rd Anniversary
Special Series in Celebration of KBR’s 4th Anniversary
ASCO 2020 Highlights
Opinion
Reporter’s Notebook
Search
트위터
페이스북
RSS
상단여백
제목보기
제목보기
제목+내용
[Exclusive] Patent of osteoarthritis drug Invossa refused in Europe
Kolon TissueGene has failed to obtain a patent for Korea’s 29th novel drug ...
by Nam Doo-hyun
|
2018-10-30 16:04
라인
CrystalGenomics to change molecular targeted therapy from injection to oral drug in trials
CrystalGenomics said it would change the form of an investigational molecul...
by Nam Doo-hyun
|
2018-10-30 10:52
라인
‘Foreign investors fear Korean botox sales decline in China’
Foreign institutional investors fear that Korean makers of botulinum toxin ...
by Nam Doo-hyun
|
2018-10-29 16:52
라인
‘Bio Solution’s value to rise on arthritis cell therapy’
Bio Solution will be able to drive up its market capitalization once it obt...
by Nam Doo-hyun
|
2018-10-25 16:30
라인
Novartis struggles to restore sales of Alzheimer’s drug Exelon
Novartis has failed to restore the sales of Exelon, a patch for the treatme...
by Nam Doo-hyun
|
2018-10-25 11:04
라인
Will synthetic biology be vital in smart therapeutics?
Synthetic biology, which designs biological components and systems in new w...
by Nam Doo-hyun
|
2018-10-24 16:40
라인
Biotech shares tank amid nosediving of Seoul stocks
Biotech and pharmaceutical shares plunged on Tuesday, hurt mainly by the ov...
by Nam Doo-hyun
|
2018-10-24 11:35
라인
Anticoagulant Lixiana outpaces Eliquis in Q3 prescriptions
Daiichi Sankyo’s Lixiana (edoxaban), a latecomer in the non-vitamin K antag...
by Nam Doo-hyun
|
2018-10-23 16:10
라인
‘Antibody drug developer AbClon noteworthy’
AbClon, a developer of innovative antibody medicines, is likely to achieve ...
by Nam Doo-hyun
|
2018-10-22 14:49
라인
'Superbug' fears bring antibiotics developers under spotlight
Investors are paying keen attention to antibiotics developers amid growing ...
by Nam Doo-hyun
|
2018-10-22 11:53
라인
Bayer’s blood thinner wins broader indication for coronary artery disease
Bayer Korea said it has obtained approval for an expanded indication for Xa...
by Nam Doo-hyun
|
2018-10-19 16:34
라인
Dental implant firms anticipate sales growth in H2
With the new policy to reduce senior patients’ payment for dental implants,...
by Nam Doo-hyun
|
2018-10-18 14:52
라인
‘Korea needs to toughen crackdown on illegal brokers for medical tourism’
The government should enhance the punishment of illegal brokers who bring i...
by Nam Doo-hyun
|
2018-10-17 15:28
라인
Relaxing requirement for innovative drugmakers will benefit Samsung, SK’
A revision bill to ease requirements for the state designation of innovativ...
by Nam Doo-hyun
|
2018-10-17 14:38
라인
CrystalGenomics hopes to test new leukemia drug early next year
CrystalGenomics said it hoped to carry out a phase-1 clinical trial on new ...
by Nam Doo-hyun
|
2018-10-16 16:17
라인
Bio stocks listed under ‘tech exception policy’ perform better
Biotech and medical companies that went public under the Korea Exchange’s “...
by Nam Doo-hyun
|
2018-10-15 12:27
라인
Anticipation grows for Lenvima as new liver cancer drug
Eisai Korea’s Lenvima (lenvatinib), recently approved as a first-line treat...
by Nam Doo-hyun
|
2018-10-11 11:44
라인
‘Korea publishes many biotech papers but rarely links them to biz’
South Korea’s ranking in biotech competitiveness, announced by the U.S. sci...
by Nam Doo-hyun
|
2018-10-10 16:35
라인
More biotech stocks come in top 20 on KOSDAQ
The number of pharmaceutical and biotech firms within the top 20 companies ...
by Nam Doo-hyun
|
2018-10-10 11:20
라인
‘Medytox performance depends on Chinese regulations on peddlers’
Medytox’s performance in the fourth quarter will rely on the Chinese govern...
by Nam Doo-hyun
|
2018-10-08 16:59
-
1
2
3
4
5
6
7
8
9
10
다음
-
176 civic groups furious over government-doctors deal
Amgen Korea wins new indication for acute lymphoblastic leukemia drug
UBcare wins patent for tech to monitor suspected infectious diseases
SCM Lifescience punished for delaying adverse reaction report
176 civic groups furious over government-doctors deal
Amgen Korea wins new indication for acute lymphoblastic leukemia drug
UBcare wins patent for tech to monitor suspected infectious diseases
SCM Lifescience punished for delaying adverse reaction report
여백
Most viewed
1
‘Cyramza helped improve gastric cancer treatment in Korea’
2
‘Reduced-dose prasugrel effective for ACS patients undergoing PCI’
3
Amgen Korea wins new indication for acute lymphoblastic leukemia drug
4
SNUBH develops AI model predicting patients at risk of cerebral aneurysm
5
Novavax releases encouraging phase-1 results on Covid-19 vaccine candidate
6
LG Chem, SK Bioscience end sales partnership with Daewoong
7
UBcare wins patent for tech to monitor suspected infectious diseases
8
176 civic groups furious over government-doctors deal
9
Recovered Covid-19 patients suffer from aftereffects – for long
10
Regulator OKs JW Pharma's rheumarthritis drug for treating giant cell arteries
여백
Opinion
[Column] Correct diagnosis leads to proper treatment
[Column] How ongoing doctors’ strike is different from 20 years ago
A Korean-American Doctor asks: Is Korea truly in 2020?
여백
Back to Top